Services Research for Autism Spectrum Disorders across the Lifespan II (ServASD II): Pilot Studies of Services Strategies for Adults with ASD (R34):

Services Research for Autism Spectrum Disorders across the Lifespan II (ServASD II): Pilot Studies of Services puzzle_logoStrategies for Adults with ASD (R34): RFA-MH-17-205
SOURCE: National Institute of Mental Health (NIMH)
APPLICATION DEADLINE: Letter of Intent: 1/3/16. Application: 2/3/16 by 5 pm local time of applicant organization.
$ AVAILABLE: NIMH intends to commit $1.3 million in FY 2017 to fund five to six awards in response to this FOA and the companion FOA.
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
ELIGIBILITY: * Public/state/private controlled institutions of higher education.
* Hispanic-serving institutions.
* Historically Black Colleges and Universities (HBCUs).
* Tribally Controlled Colleges and Universities (TCCUs).
* Alaska native and native Hawaiian serving institutions.
* Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
* Nonprofits with or without 501(c)(3) IRS status (other than institutions of higher education).
* Small businesses.
* For-profit organizations (other than small businesses).
* State governments.
* County governments.
* City or township governments.
* Special district governments.
* Indian/Native American tribal governments (federally recognized and other than federally recognized).
* Eligible agencies of the federal government.
* U.S. territories or possessions.
* Independent school districts.
* Public housing authorities/Indian housing authorities.
* Native American tribal organizations (other than federally recognized tribal governments).
* Faith-based or community-based organizations.
* Regional organizations.
PURPOSE: This Funding Opportunity Announcement (FOA) will support pilot studies to develop and test service strategies that optimize the independence and functioning of adults with autism spectrum disorders (ASD). This FOA invites preliminary studies to develop adult ASD service strategies that address enhancing social relationships, physical and mental health, and independent functioning including community housing and safety, alone or in combination. The ultimate goal of this activity is to improve functional, behavioral, and health outcomes in adults with ASD. In targeting adults, this FOA is focused on individuals who have completed transition out of services delivered via the child and adolescent service system and the primary education system.
CFDA: 93.242
CONTACT: Please see URL for multiple contacts. For more information http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-205.html
From NIH web site, accessed 10/30/15icon
Subject(s) medical research, mental health

Collaborative Aging (in Place) Research Using Technology (CART) (U2C)

Collaborative Aging (in Place) Research Using Technology (CART) (U2C): RFA-AG-16-021 seniorswalking
SOURCE: National Institute on Aging (NIA), National Cancer Institute (NCI), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), Office of Behavioral and Social Sciences Research (OBSSR)
APPLICATION DEADLINE: Letter of Intent: 12/12/15. Application: 1/12/16 by 5 pm local time of applicant organization.
$ AVAILABLE: Issuing IC and partner components intend to commit an estimated total of $6 million to fund one award over four years.
ELIGIBILITY: * Public/state/private controlled institutions of higher education.
* Hispanic-serving institutions.
* Historically Black Colleges and Universities (HBCUs).
* Tribally Controlled Colleges and Universities (TCCUs).
* Alaska native and native Hawaiian serving institutions.
* Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
* Nonprofits with or without 501(c)(3) IRS status (other than institutions of higher education).
* Small businesses.
* For-profit organizations (other than small businesses).
* State governments.
* County governments.
* City or township governments.
* Special district governments.
* Indian/Native American tribal governments (federally recognized and other than federally recognized).
* Eligible agencies of the federal government.
* U.S. territories or possessions.
* Independent school districts.
* Public housing authorities/Indian housing authorities.
* Native American tribal organizations (other than federally recognized tribal governments).
* Faith-based or community-based organizations.
* Regional organizations.
* Non-domestic (non-U.S.) entities (foreign institutions).
PURPOSE: The purpose of this, Inter-Agency Funding Opportunity Announcement (FOA) is to develop and validate the infrastructure for rapid and effective conduct of future research utilizing technology to facilitate aging in place, with a special emphasis on people from underrepresented groups.
This FOA is designed to support Collaborative Aging (in Place) Research Using Technology (CART) by developing and validating a research infrastructure that has the capacity to integrate data across different projects, incorporates existing technologies, and can accommodate future technologies, designed to assess and intervene across a variety of observational and clinical research studies and settings, and for a range of measures, diseases and populations.
CFDA: 93.399, 93.866, 93.286, 93.853, 93.361
CONTACT: Please see URL for multiple contacts. For more information see http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-16-021.html
From NIH web site, accessed 10/30/15icon
Subject(s) aged/seniors, medical research

Children with Special Health Care Needs (CSHCN) Transition Family Tool

Children with Special Health Care Needs (CSHCN) Transition Family Tool

csnch
SOURCE: Texas Health and Human Services Commission (HHSC), Texas Department of State Health Services (DSHS)
APPLICATION DEADLINE: 11/19/15.
$ AVAILABLE: The total amount of the contract that results from this RFP is for $300,000 with no more than $100,000 available for each state fiscal year throughout the term of the contract.
ELIGIBILITY: Please see URL for complete eligibility requirements.
PURPOSE: The Texas Health and Human Services Commission (HHSC) on behalf of the Department of State Health Services (DSHS) (HHSC), seeks one qualified vendor to contract with the Children with Special Health Care Needs (CSHCN) Services Program at the Department of State Health Services (DSHS) to develop a family tool to improve transition outcomes for Children and Youth with Special Health Care Needs (CYSHCN) in accordance with the specifications contained in the Request for Proposals (RFP).
CFDA: none
CONTACT: Donna Ockletree, (512) 406-2531, email: Donna.Ockletree@hhsc.state.tx.us. For more information seehttp://esbd.cpa.state.tx.us/bid_show.cfm?bidid=120926
From HHSC Procurement and Contracting Services email, 10/29/15icon
Subject(s) children’s health, health care services

B Cell Immunology Program for HIV-1 Vaccine Development (BCIP) (R01)

B Cell Immunology Program for HIV-1 Vaccine Development (BCIP) (R01)maxresdefault

Research Objectives

Emerging research findings about B cell biology need to be harnessed for developing rationally-designed vaccines against HIV-1. This FOA will support mechanistic studies with the goal of informing novel immunization strategies for generating optimal/preferable B cell responses against HIV-1.

This FOA will also support studies focused on acquiring a deeper understanding of the mechanisms by which current HIV-1 vaccine platforms induce Ab responses and the development of strategies to improve these responses. HIV-1 vaccine research is entering a time of great opportunity, and integrated approaches that dissect the mechanisms governing vaccine-induced, antigen-specific immune responses in humans will be valuable in developing an effective HIV-1 vaccine.

Specific Areas of Research Interest

This FOA is restricted to hypothesis-driven mechanistic studies. Applicants are strongly encouraged to contact, well in advance of submission, the Scientific/Research Contact  to discuss the appropriateness of the scope of the proposed project.

Areas of interest include, but are not limited to, the following:

  • Acquire a better understanding of the consequences of modulating innate and/or T cell pathways on the humoral immune response against HIV-1.
  • Explore approaches to direct B cell fate for the generation of long-term memory and persistent Ab production.  Examples may include previously established adjuvants, immunomodulators, and antigen delivery systems, either alone or in combination.
  • Identify ways to induce and maintain B cell lineages in relevant anatomical niches following vaccination against HIV-1.
  • Acquire an understanding of the relationship between the subpopulations of B cells generated during vaccination and affinity maturation or the durability of the anti-HIV-1 Ab response.
  • Studies that benchmark the response to HIV-1 immunogens against the response to other infectious agents or model systems.
  • Studies that employ multiparametric analysis (e.g. specificity, class, affinity, post-translational modifications) for profiling Ab responses to HIV-1 immunogens and the application of this knowledge to regulate desirable B cell responses in improved HIV-1 vaccine platforms.
  • Acquire an understanding of the antigenic variation, vaccine design (e.g. protein vs. DNA vs. live vector) and immunization strategies (e.g. prime-boost, differential dosing and number of immunizations, and intervals) for programming Ag-specific B cells at prime and/or during recall.
  • Studies designed to harness the role of B cells in regulating T cell immunity against HIV-1.
  • Studies to modulate desirable Ab-effector functions with durable protective properties against HIV-1 acquisition.
  • Studies exploring immunocomplexes for the maturation of the antibody response against HIV-1.

SOURCE: National Institute of Allergy and Infectious Diseases (NIAID)
APPLICATION DEADLINE: Letter of Intent: 2/17/16. Application: 3/17/16 by 5 pm local time of applicant organization.
$ AVAILABLE: NIAID intends to commit $2 million in FY2017 to fund two to three awards.
ELIGIBILITY: * Public/state/private controlled institutions of higher education.
* Hispanic-serving institutions.
* Historically Black Colleges and Universities (HBCUs).
* Tribally Controlled Colleges and Universities (TCCUs).
* Alaska native and native Hawaiian serving institutions.
* Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
* Nonprofits with or without 501(c)(3) IRS status (other than institutions of higher education).
* Small businesses.
* For-profit organizations (other than small businesses).
* State governments.
* County governments.
* City or township governments.
* Special district governments.
* Indian/Native American tribal governments (federally recognized and other than federally recognized).
* Eligible agencies of the federal government.
* U.S. territories or possessions.
* Independent school districts.
* Public housing authorities/Indian housing authorities.
* Native American tribal organizations (other than federally recognized tribal governments).
* Faith-based or community-based organizations.
* Regional organizations.
* Non-domestic (non-U.S.) entities (foreign institutions).
PURPOSE: The objective of this Funding Opportunity Announcement (FOA) is to solicit hypothesis-driven, multidisciplinary research to elucidate the complexities and developmental plasticity of B cells associated with the induction of potent, durable, adaptive immune responses against HIV-1.
CFDA: 93.855, 93.856
CONTACT: Please see URL for multiple contacts.

For more information see http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-15-055.html
From CDC National Prevention Information Network’s (NPIN) HIV/Hepatitis/STD/TB Funding Information email, 10/29/15icon
Subject(s) HIV/AIDS research

Metabolomics Data Analysis (R03)

RFA-RM-15-021

Metabolomics Data Analysis (R03)
Department of Health and Human Services
National Institutes of Health

metabolomic-data-analysis-and-visualization-tools-1-638

Specific Areas of Research Interest

Collaborations between computational and biomedical experts for the secondary analysis of existing metabolomics datasets to probe specific biomedical questions or to validate a new analytical approach could include, but are not limited to:

  • Improved methods of processing raw data for compound identification from MS/NMR peaks/features
  • Integration of metabolite data acquired across different metabolomics technological platforms
  • Metabolic modeling of known or unknown pathways with regard to a disease or disorder
  • Novel data visualizations that better uncover relationships between diseases and metabolites.
  • Validation of new methods or statistical analyses to test a specific biomedical question
  • Integration of metabolomics data with other ‘omics data to test specific biomedical questions

If analytical tools or methods are being developed, generalizable, scalable and portable solutions appropriate for scientists, not expert in informatics, are particularly encouraged. If research projects involving secondary data analyses are proposed, they could involve use of the datasets currently residing in the Metabolomics Consortium Data Repository of the Common Fund Metabolomics Program or in another publicly available database. Applicants proposing analysis of data not yet deposited or in another public database with open access must confirm willingness to share the data in accordance with all applicable rules for the protection of human subjects, which may include Department of Health and Human Services regulations at 45 CFR Part 46 and other federal and state laws that regulate the use of human subject data.

Applicants are encouraged to contact the Scientific/Research staff listed below for clarification regarding the scope of this funding opportunity.

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-RM-15-021
Funding Opportunity Title: Metabolomics Data Analysis (R03)
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.310 — Trans-NIH Research Support
Cost Sharing or Matching Requirement: No
Posted Date: Oct 30, 2015
Creation Date: Oct 30, 2015
Original Closing Date for Applications: Feb 11, 2016  
Current Closing Date for Applications: Feb 11, 2016  
Archive Date: Mar 13, 2016
Estimated Total Program Funding: $1,000,000
Award Ceiling: $100,000
Award Floor:

Eligibility

Eligible Applicants:
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Native American tribal governments (Federally recognized)
Native American tribal organizations (other than Federally recognized tribal governments)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
County governments
Special district governments
Independent school districts
Public housing authorities/Indian housing authorities
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
For profit organizations other than small businesses
Public and State controlled institutions of higher education
Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this small research grant Funding Opportunity Announcement (FOA) is to foster collaboration between bioinformaticians, metabolomics experts, and/or biomedical researchers in efforts to improve the ability to analyze metabolomics data to address biomedical questions. It is also expected that these grants would complement the current efforts of the Common Fund Metabolomics Program and maximize the value of existing metabolomics databases and resources.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-15-021.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Innovative Questions in Symptom Science and Genomics (R21)

PA-16-023
Innovative Questions in Symptom Science and Genomics (R21)DNAstethoscopesmaller
Department of Health and Human Services
National Institutes of Health

Research Objectives

Symptom Science

  • What are the biological and behavioral dynamics of symptoms (e.g., dyspnea, fatigue, impaired sleep/insomnia, pain, depression) that can change the trajectory of chronic illnesses, and how can the dynamics be optimized and maintained to prevent symptom relapse?
  • What innovative care delivery models (e.g. interdisciplinary, family-based), research methods (e.g. community engaged research, pragmatic trials) and technologies (e.g. eHealth) can be leveraged to improve symptom management and change the chronic illness trajectory especially among individuals who experience disparate health outcomes?
  • How do lifestyle factors, environmental conditions, symptom clusters and symptom treatments impact quality of life and symptom management in different chronic conditions?
  • How do symptom precursors (e.g. biomarkers or conditions such as obesity) contribute to the physiology of symptom risk, severity, duration and response to treatment?
  • What are the ‘omic’, phenotypic and state dependent indicators related to the mechanism, assessment and management of high impact symptoms (e.g. pain, fatigue, dyspnea) and what is the added value of these indicators beyond clinical parameters in explaining physical and psychological symptoms in both patients and their informal caregivers?
  • What are the common mechanistic pathways (e.g. stimulus to perception, perception to report) that can distinguish underlying symptom cluster trajectories that are amenable to intervention at various points along those pathways?
  •  What are the personalized markers (e.g. biomarkers and clinical factors) that can be used to stratify subgroups of patients with different patterns among symptoms to determine the symptom management strategies most effective in improving quality of life?
  • What innovative methodologies (e.g. modeling) can be used to analyze symptom management algorithms to identify the interventions most likely to be successful in clinical or pragmatic trials?
  • How can we create a standardized, feasible, valid, and relevant data and technology infrastructure to routinely collect and aggregate symptom data from patient health records but also from other types of assessments (biological, physiological, performance) to inform clinical care and research?
  • What are the biological indicators that can help determine the presence and severity of subjective symptoms in individuals who cannot self-report (e.g. small children; individuals with cognitive decline) to help improve clinical assessment and management? Is there a role for fMRI?
  • What state-of-the-art research designs/methods (e.g. mixed methods, SMART, MOST) should investigators use to test personalized symptom management strategies to include scalable interventions?
  • What are the biologic, physiologic and/or omic mechanisms underlying symptoms and patient outcomes?
  • Based on individual omics, environmental factors, and behavior what are the most effective and targeted interventions that can be expedited for translation to reduce risk and promote health?
  • What are the relative contributions of omic markers and phenomic data in predicting individual responses to therapeutic interventions that improve patient outcomes such as quality of life?
  • For high risk patients who are at the end of life, how can genetic assessment and DNA banking be used to address familial risk?
  • How should omic discoveries be used to create and test technologies (such as clinical tools) that can be used to diagnose clinical problems, predict the clinical course and promote optimal outcomes?
  • In what ways can genomic information be used to promote adherence and improve self-management of chronic conditions?
  • How does the social environment interact with gene expression to influence resilience in coping with life challenges?
  • The evolution and vitality of the biomedical sciences require a constant infusion of new ideas, techniques, and points of view. These may differ substantially from current thinking or practice and may not yet be supported by substantial preliminary data. By using the R21 mechanism, the NIH seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to substantially advance biomedical research.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PA-16-023
Funding Opportunity Title: Innovative Questions in Symptom Science and Genomics (R21)
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.361 — Nursing Research
Cost Sharing or Matching Requirement: No
Posted Date: Oct 30, 2015
Creation Date: Oct 30, 2015
Original Closing Date for Applications: Jan 7, 2019  
Current Closing Date for Applications: Jan 7, 2019  
Archive Date: Feb 7, 2019
Estimated Total Program Funding:
Award Ceiling: $200,000
Award Floor:

Eligibility

Eligible Applicants:
Small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Private institutions of higher education
City or township governments
Native American tribal governments (Federally recognized)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
For profit organizations other than small businesses
Independent school districts
County governments
State governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This initiative seeks to optimize innovation, insight and cutting edge conceptual and technological breakthroughs by catalyzing research that emanates from the identified innovative questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PA-16-023.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

For More Grant Opportunities on this Topic please See:

R01: http://www.grants.gov/web/grants/view-opportunity.html?oppId=279905

R15: http://www.grants.gov/web/grants/view-opportunity.html?oppId=279906

NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)

PAR-16-021
NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)
Department of Health and Human Services
National Institutes of Health

fig1

Types of Research Projects

This FOA is intended to support studies of common, complex disorders that significantly affect heart, lung, and blood (HLB) systems. Applicants should contact NHLBI staff prior to preparing an application to discuss the purpose and scope of their applications and to obtain updates regarding the technical requirements and analytical capabilities of the program. Applicants may, in a single application, apply to use one or more of the five omics assays listed above to accomplish a cohesive research goal. In accordance with the NIH Genomic Data Sharing Policy, all omics and related phenotypic data are expected to be shared with the broader research community through a public database such as dbGaP, consistent with achieving the goals of the program. Since dbGaP is built primarily for genotypic data, NIH may work with applicants to determine the details of how other omics datasets should be stored in dbGaP and/or other related databases supported by NIH.  Successful applicants will be invited and expected to join NHLBI’s TOPMed consortium and participate in its advisory and collaborative discussions.

Whole Genome Sequencing (WGS):

In general, WGS applications may aim to discover influential genetic variants underlying HLB disorders using various experimental designs (e.g., family-based, case-control, or a mix of both); if the same subjects for WGS also have other omics data, applicants may use integrative omics approaches to identify gene-regulatory networks or other functions of genomic variants. Currently, this FOA offers a standard protocol for sequencing whole human genome from high quality genomic DNA (preferably not whole genome amplified DNA). An NHLBI-designated informatics center will perform basic data processing, including variant-calling (e.g., SNPs, SNPs, and copy number variants (CNVs)) as well as submission of sequencing data to dbGaP. Applicants may also perform their own variant-calls if the standard variant-call is not appropriate to their research aims. For applicants with limited experience in or resources for handling genomic data, the sequencing centers and/or the NHLBI’s informatics center will be able to provide some genomic data analysis capacity, and those applicants will need to work with the centers to provide clinical measurements and other data required for phenotype-genotype analyses. For applications using large numbers of samples, applicants are encouraged, when possible, to divide sample collections into smaller, phased projects within a single application, starting with the minimum number of subjects needed for initial discovery. After approval to access the sequencing capacity, X01 applicants will work with NHLBI, NHGRI, and the sequencing centers to determine the timing and number of DNA samples to be sequenced.

Other Omics Assays:

Omics data other than whole genome sequence (e.g., RNA, methylation, metabolites, and proteins) may be highly useful for studies of gene-gene and gene-environment interactions. Such studies benefit from the availability of datasets which contain multi-omics data and WGS data that have all been measured on the same subjects and which also include rich clinical and environmental measurements. Because the sample preparation protocols for other omics measures (RNA-seq, DNA methylation, metabolite-profiling, and protein profiling) are expected to be more complex than that for WGS, applicants are encouraged to consult the FAQ page and contact NHLBI staff for updated protocol specifications. Large scale applications are permitted, but applicants proposing large sample sizes are encouraged to organize their study as a series of phased projects involving a smaller number of samples in each phase, if possible.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-16-021
Funding Opportunity Title: NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards: 10
CFDA Number(s): 93.233 — National Center on Sleep Disorders Research
93.837 — Cardiovascular Diseases Research
93.838 — Lung Diseases Research
93.839 — Blood Diseases and Resources Research
Cost Sharing or Matching Requirement: No
Posted Date: Oct 29, 2015
Creation Date: Oct 30, 2015
Original Closing Date for Applications: Jan 18, 2019  
Current Closing Date for Applications: Jan 18, 2019  
Archive Date: Feb 18, 2019
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
Native American tribal governments (Federally recognized)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal organizations (other than Federally recognized tribal governments)
Independent school districts
State governments
Private institutions of higher education
County governments
Public housing authorities/Indian housing authorities
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Public and State controlled institutions of higher education
City or township governments
For profit organizations other than small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. Successful applicants will provide biospecimens for whole genome sequencing or other omics assays. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public database such as dbGaP.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-021.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster